Ramsay (ASX:RHC) share price finishes higher as COVID surgery restrictions ease

Life is slowing moving back to normal for Ramsay.

The Ramsay Health Care Ltd (ASX: RHC) share price surged throughout Wednesday. This comes as the private hospital operator provider made an important announcement to investors on the ASX.

At Wednesday's closing bell, Ramsay shares finished the day 0.81% higher to $67.29.

A patient in a hospital bed is reassured by a doctor.

Image source: Getty Images

What did Ramsay announce?

In its statement, Ramsay advised that the NSW Ministry of Health that is lifting restrictions on non-urgent elective surgery. The change is for all private and public facilities within Greater Sydney and will come into effect on 25 October.

Overnight elective surgery will be capped at 75% across the board. However, private facilities within this region can exceed the cap if they are providing surgery for public patients.

In addition, the Victorian Department of Health and Human Services also made some amendments to their policy for surgical operations. Last week, only category 1 and category 2 elective surgeries have been allowed to take place across private and public hospitals.

Day surgeries can be performed in metropolitan Melbourne. There are no current restrictions on public health services or public hospitals and emergency surgery.

While a weight has been lifted off Ramsay's shoulders, it noted there will be a material impact on its earnings for FY22. This is a result of surgical restrictions in Australia along with operating in a challenging COVID-19 environment.

About the Ramsay share price

It's been a bumpy road for Ramsay shares, navigating their way through persistent lockdowns and government-mandated restrictions. Certainly, the ASX Health Care Index (ASX: XHJ) has moved sideways since this time last year, up 1%.

When compared against the Ramsay share price, over the past 12 months, its shares have moved just 3.7% higher. However, when looking at year-to-date, its shares are up more than 8%.

Based on today's price, Ramsay commands a market capitalisation of roughly $15.4 billion and has 228.88 million shares on hand.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »